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Abstract  
The activity of the transcription factor NRF2 (nuclear factor-erythroid 2 p45-derived factor 2) is 
orchestrated and amplified through enhanced transcription of antioxidant and anti-inflammatory 
target genes. The present study has characterized a thiazole-containing inducer of NRF2 and 
elucidated the mechanism by which this molecule activates NRF2 signaling. In a highly selective 
manner, the compound covalently modifies a critical stress-sensor cysteine (C151) of the E3 
ligase substrate adaptor protein KEAP1 (Kelch-like ECH associated protein 1), the primary 
negative regulator of NRF2. We further used this inducer to probe the functional consequences of 
selective activation of NRF2 signaling in Huntington’s disease (HD) mouse and human model 
systems. Surprisingly, we discovered a muted NRF2 activation response in human HD neural 
stem cells, which was restored by genetic correction of the disease-causing mutation. In contrast, 
selective activation of NRF2 signaling potently repressed the release of the pro-inflammatory 
cytokine IL-6 in primary mouse HD and wild-type microglia and astrocytes. Moreover, in 
primary monocytes from HD patients and healthy subjects, NRF2 induction repressed expression 
of the pro-inflammatory cytokines IL-1, IL-6, IL-8, and TNFα. Together, our results demonstrate 
a multifaceted protective potential of NRF2 signaling in key cell types relevant to HD pathology.  
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Significance Statement 
Chronic neuroinflammation and oxidative stress are likely complicit in driving disease 
progression in Huntington's disease (HD). Here, the mechanism of action of a novel chemical 
scaffold is described that is highly selective for activation of NRF2, the master transcriptional 
regulator of cellular anti-inflammatory and antioxidant defense genes. The use of this scaffold 
revealed that NRF2-activation responses were muted in HD patient-derived neural stem cells, 
suggesting increased susceptibility of this critical renewable cell population to oxidative stress in 
HD brain. However, pharmacological activation of NRF2 was able to repress inflammatory 
responses in mouse microglia and astrocytes, the principal cellular mediators of 
neuroinflammation, and in blood monocytes from HD patients. Our results suggest multiple 
protective benefits of NRF2 activation for HD patients. 
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Introduction  
NRF2 (NF-E2 p45-related factor 2)-mediated signaling is a major endogenous cellular 
defense mechanism against oxidative and xenobiotic stress (1-3). The transcription factor NRF2 
is tightly regulated in the cytoplasm by KEAP1 (Kelch-like ECH associated protein 1), acting as 
an adaptor between NRF2 and CUL3-based E3 ubiquitin ligase (1, 4-6). In the absence of stress, 
KEAP1 efficiently mediates the polyubiquitination of NRF2 leading to its degradation by the 
UPS (ubiquitin-proteasome degradation system) (7-10). During stress conditions, oxidants or 
electrophiles chemically modify KEAP1 sensor cysteines, causing a conformational change of the 
protein KEAP1/NRF2/CUL3 complex, and impair NRF2 degradation (11-14). De novo 
synthesized NRF2 accumulates to levels overcoming the endogenous sequestration capacity of 
the remaining free KEAP1, at which point excess NRF2 translocates to the nucleus, binds to 
antioxidant response elements (AREs) in the promoter/enhancer regions of target genes, and 
broadly activates transcriptional responses (2, 12, 15).  In this manner, NRF2 coordinates the 
transcriptional regulation of genes encoding phase II enzymes: NQO1 (NAD(P)H: quinone 
oxidoreductase 1); HO-1 (heme oxygenase (decycling) 1); catalytic (GCLC) and regulatory 
(GCLM) subunits of glutamate-cysteine ligase, and ~100 additional downstream targets (2, 16). 
Additional robust anti-inflammatory effects occur through NRF2 activation through molecular 
mechanisms that are just emerging (17). Nevertheless, there is already a strong body of empirical 
evidence in vitro and in vivo linking NRF2 activation and suppression of inflammation (18-20).  
Oxidative stress and neuroinflammation are among the common pathogenic mechanisms 
implicated in neurodegenerative disorders, including Huntington’s disease (HD) (21, 22). HD, an 
autosomal dominant and highly penetrant neurodegenerative disorder, results from the 
pathological expansion (>39) of a polymorphic trinucleotide repeat sequence (CAG)n within the 
gene encoding the large, highly conserved protein, huntingtin (HTT) (23). A harmful role for 
oxidative stress has been described in both HD patients as well as in several experimental models 
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(21, 24) which is potentially due to inherent sensitivity of neurons to damage caused by exposure 
to an excess of reactive oxygen species (ROS) (25-28). Some anti-oxidant proteins, such as 
glutathione peroxidases, catalase, and superoxide dismutase (SOD), but not all canonical ARE 
gene products, are increased in human HD brain (29), suggesting that NRF2 signaling is not fully 
engaged as a protective mechanism or may be partially repressed. Pharmacological stimulation of 
NRF2 in HD mouse models is efficacious and associated with increased expression of antioxidant 
proteins and reduction of ROS levels in brain (30, 31), which further suggests that protective 
NRF2 signaling is not fully activated and/or muted.  
Sustained brain inflammation contributes significantly to the pathogenesis of age-
dependent neurodegenerative disorders (32, 33). The release of pro-inflammatory cytokines, 
associated with the harmful effects of activated microglia in brain, creates a cytotoxic 
environment for neighboring neurons (34-36).  In HD, elevated expression of several key 
inflammatory mediators is observed in blood, striatum, cortex, and cerebellum from post-mortem 
patient tissues (37, 38). Neuroinflammatory responses appear relatively early in HD disease 
progression, suggesting that mutant HTT promotes the abnormal release of cytokines by activated 
microglia (39-41). The continual release of pro-inflammatory mediators by microglia may 
perpetuate a feed-forward cycle, recruiting and activating additional microglia, promoting their 
proliferation, and leading to additional release of pro-inflammatory factors with ever increasing 
exacerbation of disease pathogenesis (22, 40, 42-45).  
It remains uncertain whether NRF2 signaling in human HD is intact or disease-modified 
and/or differentially impacted in different cell types. Our recent work identified a new structural 
scaffold of thiazole-containing small molecules that potently induces expression of canonical 
ARE genes (NQO1, GCLM, GCLC, HMOX1/HO-1) in primary mouse cells and causes a 
pronounced reduction of reactive oxygen species (46). Here we elucidated the molecular 
mechanism by which the most potent lead compound developed from this scaffold induces NRF2 
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activation, and used this highly selective probe to examine specific activation responses and 
potential benefits of NRF2 signaling in mouse and human HD models.  
 
Results 
MIND4 is neuroprotective in MPTP-toxicity mouse model 
We first sought to evaluate the in vivo neuroprotective potential of the new structural 
scaffold of thiazole-containing NRF2 inducing compounds (46). We tested and established the 
brain permeability of MIND4 (5-nitro-8-{[5-(phenoxymethyl)-4-phenyl-4H-1,2,4-triazol-3-
yl]thio}quinoline), but we were unable to detect the presence in brain of the less hydrophobic 
analog MIND4-17 (5-nitro-2-{[5-(phenoxymethyl)-4-phenyl-4H-1,2,4-triazol-3-yl]thio}pyridine) 
(Fig. 1A, Fig. 2A, Fig. S1). Studies published to date have shown that NRF2 activation is 
protective and associated with a reduction in oxidative damage in the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) mouse model (47, 48), which was selected for a short-term efficacy 
trial with MIND4. In a pilot experiment, MIND4 was tested at two different doses in MPTP-
treated mice using a subacute treatment paradigm (49). The higher dose of 60 mg/kg attenuated 
the loss of dopamine and did not change MPTP metabolism significantly (Fig. 1B, C). Using the 
same 60 mg/kg dose and subacute regimen of treatment, we found that MIND4 was protective for 
dopaminergic neurons in MPTP mice, as demonstrated by an increased level of residual 
dopamine and a decreased dopamine turnover rate (homovanillic (HVA)/DA) in the drug-
treatment group compared to the vehicle-treated control (Fig. 1D-F). Furthermore, stereological 
analysis demonstrated that the MPTP/MIND4-treated mice had more remaining DA neurons in 
the substantia nigra than the MPTP/vehicle-treated group (Fig. 1G). Analysis of 
pharmacodynamic changes showed that treatment at the selected dose was associated with an 
increase of antioxidant NRF2-responsive GCLM protein levels, albeit not uniform among the 
treated animals (n=5) (Fig. 1H, J). The levels of acetylated α-tubulin, a prototypic substrate of 
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SIRT2 deacetylase, identified as a MIND4 target in vitro, remained largely unchanged (Fig. 1I, 
K). The results suggest that NRF2 induction contributes to MIND4 protective activity in MPTP-
treated mice.  
 
Characterization of thiazole-containing inducers of NRF2 activation  
To elucidate the mechanism of NRF2 activation, first we compared the potencies of 
MIND4, MIND4-17 and a series of structural thiazole-containing analogs in a quantitative NQO1 
inducer bioassay in murine Hepa1c1c7 cells (Fig. 2A, B; Fig. S2A) (50, 51). The CD value 
(Concentration which Doubles the specific activity) for NQO1 was used as a measure of inducer 
potency and compound ranking. Within this lead series, MIND4-17 was confirmed to be the 
inducer of highest potency (CD = 0.15 µM), comparable to the naturally-occurring inducer 
sulforaphane (SFP) (CD = 0.18 µM) and significantly more potent than the clinically approved 
NRF2 activator DMF (CD = 9 µM) (Fig. 2A, B) (52-54). A comparative analysis of MIND4-17 
and DMF on induction of NRF2-responsive NQO1 and GCLM in mutant HD rat embryonic 
striatal cells ST14A treated with compounds for 24 h clearly showed higher potency of activation 
mediated by MIND4-17 (Fig. 2C).  
As the parent compound MIND4 was initially identified as a SIRT2 inhibitor, activities 
for this lead series were also tested in a biochemical SIRT2 deacetylation assay (55). In 
agreement with our previous data (46), there was no correlation between the potencies of SIRT2 
inhibition and induction of NQO1; MIND4-17 showed no detectable SIRT2 inhibition activity 
(Fig. S2A).  
Next, we established that induction of NQO1 by MIND4-17 and other structural analogs 
is NRF2-dependent. NQO1 expression was assessed over a series of concentrations in wild-type, 
NRF2-null, or KEAP1-null mouse embryonic fibroblasts (MEF) after 24 h treatment (56-59). In 
wild-type MEFs, MIND4-17 exhibited the highest potency, while other MIND4 analogs 
increased the levels of NQO1 protein to varying degrees (Fig. S2B). In contrast, the effects of 
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MIND4-17 and other MIND4 analogs on induction of NQO1 expression were absent in NRF2-
null cells (Fig. 2D). In KEAP1-null MEFs, which have constitutively high transcription of NRF2-
responsive genes (57, 59), treatment with MIND4-17 and other MIND4 analogs did not 
upregulate NQO1 expression further (Fig. S2C). These results demonstrated that induction of 
NQO1 expression by MIND4-17 and other structural analogs is NRF2-dependent and KEAP1-
dependent.  
Stabilization of NRF2 is an essential step of activation of the pathway, which has been 
well-defined for KEAP1-modifying inducers of NRF2 signaling such as sulforaphane (SFP) (7, 8, 
52, 58). Thus we tested whether the stabilization of NRF2 in cells treated with MIND4-17 and its 
structural analogs preceded the induction of NQO1. Accumulation of total NRF2 protein was 
readily detectable in wild-type MEFs after 5 h exposure to SFP and MIND4-17 and, to a lesser 
extent, to the lower potency inducers MIND4 and MIND4B (Fig. 2E). In cells treated with 
MIND4-17, the induction of NQO1 was preceded by nuclear accumulation of NRF2 as early as 
30 min after cell exposure to MIND4-17 (0.5 µM) and remained elevated for at least 5 h (Fig. 
2F).  
 
NRF2 inducing mechanism of MIND4-17  
The chemical requirements for the NRF2 inducing activity of MIND4-17 became evident 
from a structure-activity relationship (SAR) study (Fig. S3, please see Supporting Information 
for detailed compound synthesis schemes) (60, 61). Analogs of MIND4-17 with O or C 
substitutions of the S atom were completely inactive, illuminating the essential requirements for 
the sulfur for inducer activity (Fig. S2D-F). The dependence of inducer activity on an electron-
withdrawing group and electron-deficient aromatic system was also apparent (Fig. S2D-F). 
Together, these results suggested that the S group of MIND4-17 could be chemically reactive 
with cysteine nucleophiles, and that this property is essential for NRF2 activation.  
To test this hypothesis, MIND4-17 and other thiazole-containing analogs were pre-
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incubated with reduced glutathione (GSH) followed by incubation with intact cells and 
measurement of NRF2 activation responses.  Such pre-treatment negatively affected the ability of 
MIND4-17 to induce the NRF2 response (Fig. S2F, G). Further, pre-incubation with GSH 
inhibited NRF2 inducer activity in direct correlation with NRF2 activation potency; i.e., MIND4-
17 was the most strongly reactive and thus the most profoundly negatively affected. These results 
indicated that the reactivity of the S group is essential for MIND4-17 mediated activation of 
NRF2 and involves reaction with cysteine nucleophile(s) of putative target(s). 
It is well established that reactive cysteine residues of KEAP1 serve as sensors for 
electrophiles and oxidants, and that chemical modifications of these cysteines disable the 
KEAP1/CUL3 complex, ultimately leading to NRF2 activation (7, 11, 12, 53, 62). Located within 
the BTB domain (Broad complex, Tramtrack and Bric-à-Brac domain), cysteine-151 (C151) is 
one of the major sensors in KEAP1, the modification of which is sufficient for robust activation 
of NRF2 (7, 12, 53, 63-65). It was therefore conceivable that C151 of KEAP1 is targeted by 
MIND4-17. To investigate this possibility, we purified recombinant BTB domain of KEAP1 
protein and examined by mass spectrometry its covalent modification in the absence or presence 
of MIND4-17 (66). The mass for the protein incubated with DMSO (control reaction) was 
determined to be 16175.6 Da, in good agreement (within <10 ppm) to its calculated mass of 
16175.7686 Da (Fig. 2G). Incubation of BTB with MIND4-17 resulted in a reduction in the peak 
for the non-modified protein, and the emergence of a dominant peak at 16298.0 Da, indicating 
covalent modification of the protein. The observed shift of 122.4 Da was as would be predicted 
for a single cysteine being modified by formation of a 3-nitropyridine adduct with MIND4-17 
(calculated mass difference 123.09 Da). 
Next, we validated the putative KEAP1-modyfying mechanism of NRF2 activation by 
MIND4-17 in live cells (7, 53). COS1 cells were co-transfected with plasmids encoding NRF2-
V5 and either KEAP1 wild-type, mutant C151S (cysteine-151 is replaced by serine), or double-
mutant C226S/C613S; β-galactosidase was used to monitor transfection efficiencies.  In accord 
 10 
with our previous observations, MIND4-17 stabilized NRF2 in cells expressing wild-type KEAP1 
(Fig. 2H). In cells expressing a double mutant C226S/C613S KEAP1, MIND4-17 was still able 
to stabilize NRF2 protein to levels similar to those for wild-type KEAP1 (Fig. 2H). In contrast, 
MIND4-17 failed to stabilize NRF2 in cells expressing the single C151S mutant KEAP1 (Fig. 
2H). These results therefore were consistent with MIND4-17-dependent activation of NRF2 
through a highly selective and covalent modification of the KEAP1 sensor cysteine C151. 
To determine if MIND4-17 promiscuously alkylated other reactive cysteines within the 
proteome, we utilized a quantitative cysteine-reactivity profiling strategy to globally identify 
cysteine residues that demonstrate significant loss of reactivity upon pre-incubation with 
compounds (67, 68). Briefly, a promiscuous cysteine reactive iodoacetamide-alkyne (IA) probe 
coupled to isotopic linkers was used to monitor changes in cysteine reactivity by quantitative 
mass-spectrometry (MS) (69-71). (For detailed protocol please see Supporting Information). Of 
the >300 reactive cysteine-containing peptides identified in our MS studies, only 4 residues 
showed a >2-fold change in cysteine reactivity upon treatment with MIND4-17 (SI Dataset). 
Within the subset of cysteines with no change in reactivity were hyper-reactive cysteine residues 
such as the active-site nucleophile of GAPDH, attesting to the low reactivity of the MIND4-17 
across even highly reactive cysteines within the proteome.  
 
MIND4-17 causes conformational change in the KEAP1:NRF2 protein complex in live cells  
We further validated the MIND4-17 mechanism of NRF2 activation using a recently 
developed FRET/FLIM methodology (14, 72) and examined whether MIND4-17 treatment 
arrests the KEAP1/NRF2 complex in the closed conformation, thus permitting de novo NRF2 
accumulation and translocation in nuclei to activate ARE-gene transcription. The effects of 
MIND4-17 on the conformational changes of the KEAP1:NRF2 complex were determined in 
HEK293 cells ectopically expressing fluorescent EGFP-NRF2 and KEAP1-mCherry fusion 
proteins, or EGFP-NRF2 and free mCherry as a negative control. As expected, in vehicle-treated 
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cells transfected with EGFP-NRF2 and free mCherry, most of the NRF2 was in the nucleus (Fig. 
3A, first row, images), and the lifetime of EGFP fluorescence in the cytoplasm was 2324 ± 7 ps 
(n=6) (Fig. 3A, first row, graph). When KEAP1-mCherry was co-expressed with EGFP-NRF2, 
NRF2 was largely cytoplasmic (Fig. 3A, second row, images), and the EGFP lifetime was 
significantly reduced to 2184 ± 42 ps (n=6, p=1.14E-05) (Fig. 3A, second row, graph), 
indicating the occurrence of FRET between the fluorophores and demonstrating that the two 
fusion proteins interact. No significant changes were observed in the sub-cellular localization of 
EGFP-NRF2 upon addition of MIND4-17 to cells co-expressing EGFP-NRF2 and free mCherry 
(Fig. 3A, third row, images and graph). In contrast, exposure to 1 µM of MIND4-17 for 1 h 
promoted the nuclear accumulation of EGFP-NRF2 in cells co-expressing EGFP-NRF2 and 
KEAP1-mCherry (Fig. 3A, fourth row, images), and the EGFP lifetime was significantly 
reduced further to 2147 ± 50 ps (n=17, p=5.98E-09) (Fig. 3A, fourth row, graph).  
Further quantification of the FRET efficiency revealed that, in the cytoplasm of vehicle-
treated cells, 62% of the KEAP1:NRF2 complex was in the open conformation, and 38% in the 
closed conformation. Treatment with MIND4-17 inverted this ratio to 44% and 56% of 
KEAP1:NRF2 complexes being in the open and the closed conformations, respectively (Fig. 3B). 
These results obtained by FRET/FLIM analysis in live cells showed that MIND4-17 arrests the 
NRF2:KEAP1 protein complex in the closed conformation, which is similar to previously 
reported effects of the electrophilic NRF2 inducers sulforaphane and sulfoxythiocarbamate 
alkyne (13) but in contrast to the effects of the non-electrophilic triazole inducer HB229, which 
directly disrupts the KEAP1:NRF2 protein:protein interaction (73).  
Taken together, these data delineate a mechanism of NRF2 activation by MIND4-17 
through specific covalent modification of KEAP1 sensor-cysteine C151, subsequently causing 
accumulation and nuclear translocation of de novo synthesized NRF2, and activation of NRF2-
dependent gene transcription. Thus, MIND4-17 acts as a highly KEAP1-selective stress-
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mimicking compound (74), and was next employed for investigating NRF2 signaling responses in 
HD models systems. 
 
NRF2 activation by MIND4-17 induces anti-inflammatory effects in microglia and 
macrophages  
NRF2 activation-dependent anti-inflammatory responses have been well described in 
microglia cells (75, 76). It has been also shown that genetic or pharmacologic NRF2 activation 
counteracts release of pro-inflammatory cytokines in the context of exposure to UV radiation 
(20). Thus, we first validated the effect of MIND4-17 treatment on repression of pro-
inflammatory cytokines in microglial cells and also in peripheral macrophages which are known 
to infiltrate CNS in late-stage HD. As expected, treatment of mouse microglial BV2 cells with 
MIND4-17 resulted in a potent and concentration-dependent increases in transcription of the 
canonical ARE genes GCLM and NQO1 in both resting and lipopolysaccharide (LPS)-activated 
microglial cells (Fig. 4A, B). Concomitantly, treatment with MIND4-17 resulted in a 
concentration-dependent repression of the pro-inflammatory factors IL-6, IL-1β, TNFα, and 
MCP-1 (Fig. 4C-F). MIND4-17 treatment similarly repressed IL-6, IL-1β, TNFα, and MCP-1 and 
activated NQO1 and GCLM genes in resting and LPS-stimulated bone marrow-derived 
macrophages (Fig. S4) (77).  
 
Anti-inflammatory NRF2 activation response in HD and wild-type primary mouse 
microglia and astrocytes  
Having established that MIND4-17 represses cytokine expression, next we probed for 
anti-inflammatory effects of NRF2 activation in brain-resident non-neuronal cells, namely 
microglia and astrocytes, and specifically examined the effect on release of IL-6, an established 
marker of inflammation in HD model systems (40, 78).  
MIND4-17 was first evaluated for its impact on inflammatory responses in primary 
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microglia derived from wild-type and HD mutant YAC128 mice (79). The YAC128 mouse model 
of HD expresses the full-length human transgene with 128 CAG repeats and replicates key 
elements of HD phenotypes and selective neurodegeneration. Previous studies in peripheral blood 
monocytes from YAC128 mice focused on IL-6 as a marker of inflammation in HD (80). Release 
of IL-6 from wild-type and YAC128 microglia was induced by stimulation with control standard 
endotoxin (CSE) and INF-γ. MIND4-17 reduced the amount of IL-6 secreted from wild-type and 
YAC128 primary microglia in a concentration-dependent manner and in highly similar fashion 
(Fig. 4G). Experiments were next extended to primary astrocytes derived from wild-type and 
YAC128 mice.  MIND4-17 treatment resulted in a similar concentration-dependent reduction of 
IL-6 release in CSE-stimulated primary astrocytes derived from YAC128 and wild-type mice 
(Fig. 4H).  
Taking advantage of the brain permeability of the MIND4 analog, which, similar to 
MIND4-17, repressed cytokine expression in LPS-induced microglia (Fig. S4G), we next 
conducted a semi-acute 2-week treatment of symptomatic HD R6/2 mice (81). A statistically 
significant reduction of cortical TNFα levels was detected (Fig. S4H-K), consistent with the anti-
inflammatory effects of the NRF2 activation observed in primary mouse microglia and astrocytes 
(Fig. 4G, H) These results suggest that the anti-inflammatory NRF2 activation response remains 
available for induction in symptomatic R6/2 mice with well-progressed HD neurological 
phenotype.  Interestingly, cortical TNFα levels were not significantly different between untreated 
wild type and R6/2 mice (Fig. S4, J), suggesting the TNFα itself is unlikely to be the sole driver 
of neuroinflammation in HD.   
 
Anti-inflammatory NRF2 activation responses are intact in primary monocytes from HD 
patients  
Finally, to validate these HD model results in human HD, the anti-inflammatory effects of NRF2 
induction by MIND4-17 were examined in primary human monocytes derived from HD patients 
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and non-disease controls. Ex vivo peripheral immune cells from HD patients produce significantly 
more pro-inflammatory cytokines in response to LPS and INF-γ stimulation than cells isolated 
from control subjects (40, 78). Here, we induced production of the pro-inflammatory cytokines 
IL-1, IL-6, IL-8, and TNFα in primary monocytes by stimulation with LPS and INF-γ. Pre-
treatment with MIND4-17, prior to induction with LPS/ INF-γ significantly decreased the levels 
of all four pro-inflammatory cytokines in both HD and control monocytes (Fig. 5, Fig. S5A-D). 
In HD monocytes, MIND4-17 significantly repressed the expression of all four cytokines at the 3 
µM and 1 µM concentrations and repressed IL-8 and TNFα expression at the lowest tested 
concentration of 0.3 µM, demonstrating a highly similar pattern of the compound effects in the 
disease and non-disease counterparts. Neither vehicle (DMSO) nor MIND4-17 affected the 
viability of primary human monocytes at any of the concentrations tested (Fig. S5E).  
The responses in human monocytes were consistent with the effects observed in the 
mouse models. Overall, the results suggest that NRF2 activation in non-neuronal primary HD 
cells is intact, amenable to activation, and capable to mediate anti-inflammatory protective 
responses.  
 
NRF2 activation responses are muted in human HD neural stem cells  
We next evaluated NRF2 activation responses in experimental neural HD models of 
human origin. Nestin-positive HD48 (mutant 42CAG) and HD51 (mutant 51CAG) and non-
disease WT55 and WT54 neural stem cells (NSCs) were differentiated from human iPSCs, based 
on a protocol described for mouse ES cells (82) (Fig. S6; please see Supporting Information for 
detailed protocols). Cells were treated for 24 h with MIND4-17 at a concentration range of 0.1-3 
µM, and levels of the canonical NRF2-responsive proteins NQO1 and GCLM (Fig. 6A) and HTT 
(Fig. 6B) were examined by immunoblotting. The levels of NQO1 were significantly higher in 
both HD cell lines and thus a lower amount of protein per lane was loaded to illuminate the 
compound effects (Fig. 6C; note multiple NQO1 molecular weight bands reflecting known 
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protein isoforms).  Treatment with MIND4-17 induced a concentration-dependent increase of the 
NRF2-responsive proteins NQO1 and GCLM in HD and non-disease cells. The MIND4-17-
dependent increase of NQO1 and GCLM levels started at 1 µM in both HD and at 0.1 µM in both 
non-disease cell lines. MIND4-17 treatment had no detectable effects on HTT levels. 
To determine if the magnitude of NRF2 response varied in HD versus non-disease cells, 
we compared the maximum fold-induction of NQO1 expression. A maximal ~2-fold response 
was observed in each HD cell line at 3 µM of MIND4-17 (Fig. 6D, E). Non-disease WT cells 
showed a maximum ~4-fold response at 1 µM of MIND4-17, which plateaued by 3 µM (Fig. 6D, 
E). These data suggest that NRF2 induction could be compromised in HD due to suppressive 
influence of the expanded CAG repeat mutation on pathway activation; alternatively, a reduced 
fold-change in response to MIND4-17 could be due to a pre-existing partial or full activation in 
response to mHTT-induced homeostatic changes in the HD cells.  
To distinguish between these two possibilities, we compared responses in NSC HD4 with 
a severe 72 CAG mutation and its isogenic-counterpart NSC HD116c, in which the 72 CAG 
expansion was corrected to a non-pathological 21 CAG repeat length by homologous 
recombination (83). In HD4 NSCs the basal levels of NQO1 and GCLM proteins were similar to 
HD116c (Fig. 6F), indicating the NRF2 pathway was not partially activated. Treatment with 
MIND4-17 did not induce a significant increase of either NQO1 or GCLM expression in HD4 
cells (Fig. 6G, I, J).  In sharp contrast, MIND4-17 treatment induced a concentration-dependent 
increase of NQO1 and GCLM expression in HDc116 cells (Fig. 6H, K), similar to that observed 
in WT54 and WT55 NSCs (Fig. 6A). The induction of both NRF2-responsive proteins in the 
corrected HDc116 cells was significant at 0.3 µM concentration of MIND4-17. A maximum 4-
fold response was observed at concentrations 1 and 3 µM, which was similar to the response in 
non-disease NSCs.  
Together, these data show that the HD mutation negatively impacts NRF2 signaling and 
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suggest that interference is even greater for the extreme CAG pathological expansions, which are 
associated with juvenile clinical cases. 
 
Discussion  
In the present study we have developed and determined the mechanism of action of a 
novel and highly selective small molecule inducer of NRF2 signaling, MIND4-17. The NRF2 
signal transduction cascade is initiated by MIND4-17 through highly selective, covalent 
modification of the KEAP1 sensor-cysteine C151, mimicking effects of oxidative and 
electrophilic stress (10, 12, 53, 63). This chemical modification of KEAP1 leads to 
conformational change and arrest of the KEAP1/NRF2 complex in the closed conformation, 
disrupting the cycle of degradation of NRF2 (13, 66, 74). Subsequently, this results in 
accumulation (stabilization) and nuclear translocation of de novo-synthesized NRF2, followed by 
NRF2-mediated activation of gene expression. Proteomic analysis showed high MIND4-17 
selectivity for the KEAP1 target, which makes this compound an attractive probe for 
investigating the activation of NRF2 signaling (74). 
A highly specific KEAP1-modyfing inducer probe such as MIND4-17 has key 
advantages over genetic manipulations or broadly unspecific oxidants or electrophiles for 
investigating endogenous biological responses specific to NRF2 signaling in stress. For example, 
the gene silencing of KEAP1, whose expression is NRF2-dependent, would disrupt an auto-
regulatory loop (84) and, due to the absence of natural formation of the substrate adaptor and E3 
ubiquitin ligase KEAP1/CUL3 complex, would result in over-activation of the NRF2 pathway 
(47). Moreover, in contrast to small organic inducers like DMF and SFP, which lack selectivity 
and "SAR-ability," the novel MIND4-17 scaffold presented here is drug-like and amenable to 
further chemical modifications to optimize its pharmaceutical properties.  In this context, a key 
pharmacokinetic property requiring further optimization will be brain permeability, which is 
minimal for MIND4-17 itself and precludes its direct consideration as a clinical candidate.  
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While mutant HTT is ubiquitously expressed and impacts multiple cell types across all 
bodily tissues, we next investigated NRF2 signaling in the non-neuronal cell populations that are 
the principal mediators of neuroinflammation, namely, microglia, astrocytes and peripheral 
monocytes, and in the context of both mouse and human HD model systems.  Our results showed 
that the selective NRF2 inducer MIND4-17 repressed expression of pro-inflammatory cytokines 
in primary microglia and astrocytes from HD and wild-type mice (40, 78). Similar effects were 
observed in human primary monocytes from HD patients and normal subjects, in which MIND4-
17 mediated repression of pro-inflammatory cytokines in both disease and non-disease cells. 
Based on these results, we concluded that NRF2 and downstream anti-inflammatory pathways are 
intact and not affected by the HD mutation in these non-neuronal populations.  
This finding is especially important as dysfunction in non-neuronal cell types is 
recognized as a potential contributor to neurodegeneration, in which a critical role for activated 
microglia in HD has emerged (85).  The release of pro-inflammatory cytokines, associated with 
the harmful effects of activated microglia in brain, creates a cytotoxic environment for 
neighboring neurons (34-36). The potential therapeutic benefits of NRF2 activation are 
increasingly appreciated to originate in glial and CNS-relevant immune cells including microglia 
and peripheral macrophages (86). Thus, the results from our studies highlight the therapeutic 
potential of NRF2 signaling to repress pro-inflammatory processes in the brain parenchyma 
including astroglia, microglia, and infiltrating peripheral macrophages.  
NRF2 activation responses were evaluated in human NSCs derived from patient iPSCs. 
NSCs can give rise to neurons, astrocytes, oligodendroglia and in HD exhibit phenotypes that 
may be pathologically relevant (83, 87). Moreover, there is evidence that the pool of adult NSCs 
is depleted in the striatum of HD patient brains (88) and may further contribute to HD pathology 
over time. Our results showed that in HD NSCs with a CAG repeat expansion in the range typical 
for adult-onset disease, NRF2 responses were muted compared to non-disease counterparts. 
Induction of NRF2 responses were essentially silent in NSCs with an extreme CAG repeat length 
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associated with juvenile onset, but were restored to non-disease levels upon isogenic genetic 
correction of the CAG expansion. Our data showed that in the context of human HD NSCs, NRF2 
signaling is muted, which was consistent with similar observation in the striatal STHdh mHTT 
Q111/Q111 cell line (89), although it is yet unclear whether mHTT is directly involved. The results 
imply a high stress-sensitivity of HD NSCs in adult brain, which could offer an explanation for 
depletion of these cells in the course of disease (88).  
Taken together, our results highlight a differential and complex NRF2-dependent stress-
response in human brain and emphasize potential therapeutic benefits of NRF2 activation for HD 
treatment.    
 
Materials and Methods 
Compound source and storage  
Compounds were procured from ChemBridge Corp. San Diego (purity QC ensured by provided 
NMR spectroscopy data), dissolved in molecular biology grade dimethyl sulfoxide (DMSO) to 10 
mM stock concentrations, aliquoted, and stored at -80°C. MIND4-17 was re-synthesized (purity 
>95%) and showed essentially identical potency of NRF2 activation to MIND4-17 in multiple 
batches purchased from ChemBridge. Design and schemes for synthesis of MIND4-17 analogs 
2872, 2286, 2291, 2907, and 2909 can be can be found in Supporting Information. Dimethyl 
fumarate was purchased from Sigma and sulforaphane from LKT Laboratories, Inc.  
Drug test in MPTP mouse model  
MIND4 was solubilized at 5mg/ml in 7.5% Cremophor EL (BASF)/2.375% Ethanol in PBS. 
Please see Supporting Information for details on tolerability and brain-permeability studies. 
Male C57BL/6 mice (~25 g) from Charles River Laboratories, Wilmington, MA were housed in 
temperature- and humidity-controlled rooms with a 12 h dark: light cycle and had free access to 
food and water. Subacute MPTP paradigm (20 mg/kg i.p. injection once daily for 4 days) was 
employed to test dose response of MIND4 (90) at 30 mg/kg or 60 mg/kg, (i.p. 10min before and 
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50min after each MPTP injection). The effective dose of 60 mg/kg was used in the subsequent 
experiments. Control animals received saline (control for MPTP) and 10% propylene glycol and 
90% dextrose as vehicle for MIND4 by i.p. Mice were sacrificed 7 days after the last MPTP 
administration and striatal DA and metabolite HVA were determined by high performance liquid 
chromatography (HPLC) coupled with electrochemical detection (ECD) (90). Immunostaining for 
tyrosine hydroxylase (TH), a marker for dopaminergic neurons was performed using mouse anti-
TH antibody (Sigma, ST. Louis, MO). Total numbers of TH positive neurons in the substantia 
nigra (SN) were counted under blinded conditions using the Bioquant Image Analysis System 
(R&M Biometrics, Nashville, TN) (91).  
NQO1 bioassay 
Inducer potency was quantified by use of the NQO1 bioassay in Hepa1c1c7 cells as described 
(50, 51). In brief, cells grown in 96-well plates were exposed to serial dilutions of each compound 
for 48 h, and the NQO1 enzyme activity was determined in cell lysates. Results are shown as 
average values of 8 replicate wells. The standard deviation in each case was less than 5%. 
Compound activity test in the rat embryonic striatal cell lines ST14A 
ST14A cells (a generous gift of E. Cattaneo) (92) stably express either a mutant expanded repeat 
(128Q) or wild-type (26Q) 546 amino acid huntingtin (HTT) fragment and were treated with 
compounds for 24 h as described (93). Please see Supporting Information for information on 
antibodies.  
Compound activity test in mouse embryonic fibroblasts  
Mouse embryonic fibroblasts (MEFs) from wild-type (WT), NRF2-knockout (NRF2-KO) or 
KEAP1-knockout (KEAP1-KO) mice (59) were cultured in plastic dishes (Invitrogen) coated for 
30 min with 0.1% (w/v) gelatin. For experiments, cells (250,000 per well) were grown for 24 h on 
6-well plates, and then treated with solvent control (0.1% DMSO, v/v) or compounds for 24 h. 
For Western blot analysis cells were lysed in RIPA buffer, containing 1 protease inhibitor 
cocktail tablet (Roche) per 10 mL buffer. Proteins were resolved by SDS-PAGE and 
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immunoblotted with specific antibodies against NQO1 (1:1000) or NRF2 (1:1000), both gifts 
from Professor John D. Hayes, University of Dundee, and β-actin (Sigma, mouse monoclonal, 
1:10000).  Conventional method was used to separate nuclear and cytoplasmic fractions to test 
NRF2 induction and stabilization (please see Supporting Information for details).  
Cell-based KEAP1-target validation assay  
COS1 cells were plated 16 h before transfection, followed by co-transfection with plasmids 
encoding wild-type, mutant C151S, or C226S/C613S double-mutant KEAP1 and NRF2-V5 
(generous gifts from Dr. M. MacMahon and Professor John D. Hayes, University of Dundee) at 
1:1 ratios. A plasmid encoding β-galactosidase was co-transfected to monitor transfection 
efficiency. 24 h post-transfection, cells were exposed to MIND4-17 for 3 h, extracts were 
prepared and loaded on SDS-PAGE normalized by β-galactosidase  activity. Samples were 
resolved on SDS-PAGE and immunoblotted with antibodies against KEAP1 (1:2000, rabbit 
polyclonal, a kind gift from Professor John D. Hayes, University of Dundee) and V-5 (1:5000, 
mouse monoclonal, Invitrogen).    
Fluorescence lifetime imaging analysis of NRF2:KEAP1 complex  
HEK293 cells (200,000 per dish) grown in standard media in 6 cm glass dishes were co-
transfected with constructs encoding EGFP-NRF2 and KEAP1-mCherry using Lipofectamine 
2000 (Invitrogen) as described (13). Cells were imaged 24 h post-transfection before and after 1 h 
exposure to 1 µM MIND4-17. All images were acquired by confocal microscopy using a laser-
scanning confocal microscope (LSM780; Carl Zeiss). The microscope was equipped with a 
thermostatic chamber suitable to maintain the live cells and optics at constant 37°C. Imaging was 
performed using a 63x oil immersion NA 1.4 Plan-Apochromat objective from Zeiss. 
Fluorescence lifetime imaging microscopy (FLIM) was performed as described (94). Specific 
details of analysis are provided in Supporting Information.   
Mass spectrometry analysis of KEAP1 modification(s)  
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Expression and purification of recombinant BTB and full-length KEAP1 proteins are described in 
details in the Supporting Information. To analyze covalent modification(s) of the BTB domain, 
10 µM BTB [48-190 S182A] were incubated with 2 mM MIND4-17 (or 2% DMSO final 
concentration for control) for 1 h on ice in 20 mM Tris-HCl pH 8.0, 150 mM NaCl. Intact protein 
masses were determined through HPLC-coupled ESI-MS on an AB Sciex TripleTOF 5600+ mass 
spectrometer (Sciex) as described in detail in Supporting Information.  
NRF2-dependent transcriptional profiling of MIND4-17 in BV2 microglia cells  
The BV2 mouse microglial cell line was a generous gift from Dr. Michael Whalen 
(Massachusetts General Hospital). Cells were maintained in DMEM media (Invitrogen) 
supplemented with 10% FBS (Sigma) and antibiotic-antimycotic mix (Invitrogen). Cells were 
seeded into 12-well plates at the density of 3x105 cells/well. Cells were treated with the indicated 
concentrations of MIND4-17 for 24 h. Cells were then stimulated with 10 ng/ml LPS (E.coli, 
Sigma) for 2 h. Total RNA was isolated using ZR Miniprep kit (Zymo Research). 1 mg of total 
RNA was used to prepare cDNA (ProtoScript kit, New England Biolabs). Gene expression levels 
for NQO1, GCLM, IL1, IL6, TNFα, and MCP1 were analyzed by the VeriQuest SYBR green 
assay (Affymetrix) using a Roche480 thermocycler. The sequences of gene-specific primers for 
qPCR can be found in the Supporting Information.   
MIND4-17 activity test on cytokine IL-6 release in primary mouse astrocytes and microglia  
Whole brains were obtained from postnatal 1 to 3 d old wild-type and YAC128 mouse pups on 
the FVB/N strain background and placed in Hank's Balanced Salt Solution (Invitrogen) on ice. 
Meninges were removed and the remaining brain tissue was placed into growth medium (DMEM, 
10% FBS, 1% L-glutamine, 1% penicillin/streptomycin), and homogenized. Please see details on 
cell isolation and culturing in Supporting Information. After the initial isolation microglia and 
astrocytes were seeded at a density of 1.4 x 105 cells/ml into 96-well tissue culture plates. 24 h 
later, the culture media was replaced with media containing MIND4-17 at different 
concentrations in growth medium containing 1% FBS. 24 h later medium containing interferon-γ 
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(INF-γ; final concentration 10 ng/ml; R&D Systems) with CSE (Control Standard Endotoxin, 
Associates of Cape Cod) at a final concentration 100 ng/ml. Supernatants were collected at 9 h, 
and stored at -20°C. Cells were lysed and total protein levels were determined using the micro 
BCA kit (Thermo Scientific). Supernatants were analyzed using mouse IL-6 ELISA (e-Biocience) 
and IL-6 levels normalized to total protein levels. 
MIND4-17 activity test on cytokine expression in primary human HD and non-disease monocytes 
All human experiments were performed in accordance with the Declaration of Helsinki and 
approved by University College London (UCL)/UCL Hospitals Joint Research Ethics Committee. 
All subjects provided informed written consent. Blood samples were obtained from control 
subjects and genetically-diagnosed, symptomatic HD patients. Patients were classed as having 
early or moderate-stage disease using the total functional capacity (TFC) scale (13-7, early; 6-3, 
moderate) (95). Subjects with inflammatory or infective conditions were excluded.   
Information on cohorts of HD and healthy subjects participated in the study: 
HD (n=13): age=56.84 +/- 9.23; CAG repeats= 42.46 +/- 1.80; female/male ratio=53/47.   
Healthy subjects (n=10): age=49.98 +/- 15.03; female/male ratio=53/47. 
Cells were isolated from whole blood, as previously described (40). (Please see Supporting 
Information for details). After resting for 16 h, the culture media was replaced with R10 media 
containing either vehicle (DMSO) or MIND4-17 at different concentrations (0.3, 1, and 3 µM). 
After 24 h treatment, media was changed again using R10 containing both MIND4-17 at the same 
concentration and, to stimulate cytokine production, 10 ng/ml INF-γ (R&D Systems) and 2 
mg/ml lipopolysaccharide (LPS, Sigma-Aldrich). Supernatants were collected at 24 h and 
analyzed using the human pro-inflammatory II (4-plex) MSD assay measuring IL-1β, IL-6, IL-8 
and TNFα. Normalized cytokine levels were analyzed on a logarithmic scale due to their skewed 
distribution. Statistical analysis was performed using a linear mixed model, to allow for 
correlation between measurements from the same subject. A constant correlation was assumed 
between all 6 measurements from each subject, with robust standard errors to allow for deviation 
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from this assumption. An advantage of this approach is that linear mixed models provided 
unbiased estimates of each comparison even if there were missing data, provided the data was 
assumed to be missing at random. Contrasts of interest were then calculated using linear 
combinations of parameter estimates.  
MIND4-17 activity test in human neuronal stem cells (NSCs) 
iPSCs were obtained from NINDS Repository at the Coriell Institute for Medical Research: Cat# 
ND38554 (named here WT54); Cat# ND3855 (WT55); Cat# ND38551 (HD51); Cat# ND38548 
(HD48). The HD4 cell line harbors a severe juvenile repeat range 72 CAG mutation; in the 
isogenic-companion cell line HD116c the pathological mutant CAG expansion was corrected to a 
non-pathological 21 CAG repeat by homologous recombination (83). Genotype was confirmed by 
PCR amplification of genomic DNA (Fig. S6A). Please see Supporting Information for 
additional details on maintenance iPSCs. NSCs were established based on a protocol described 
for mouse ES cells (82) and detailed protocol is provided in Supporting Information. For 
compound treatments, cells were plated at 100,000 cells/well on poly-L-lysine/laminin coated 24-
well plates. Compound was diluted to 2x the final concentration in complete medium then an 
equal volume of solution was added to each well.  The final concentrations of MIND4-17 were 0-
3 µM. An equal volume of carrier (DMSO) was used as a control. Cells were treated for 24 h then 
lysed in buffer and analyzed by SDS-PAGE and Western blot. 
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 Figure Legends 
 
Fig. 1. MIND4 is neuroprotective in MPTP-toxicity mouse model. A) Brain-permeability of 
MIND4, administered by intraperitoneal (i.p.) injections to wild type mice. Chromatograms of 
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MIND4 standard (1µg/ml) and MIND4-treated brain are shown. HPLC analysis detected MIND4 
at 0.45 µg/ml concentration in mouse cortical extracts, providing preliminary evidence for 
compound brain permeability. B) MIND4 effective dose was established in mice using subacute 
MPTP treatment paradigm: MPTP untreated control (CTR) and MPTP treated mice with 
administered by i.p. vehicle alone or with MIND4 at  30 and 60 mg/kg dose. Vehicle or MIND4 
were administered 10 min before and 50 min after each MPTP injection. Levels of dopamine 
(DA) were determined by HPLC-ECD. Statistical significant increase of DA was observed in 
mice treated with MIND4 at 60mg/kg. n=5-8  * = p < 0.05; ** = p <0.01. C) MIND4 at 60mg/kg 
before and after administration of 20mg/kg MPTP does not change metabolism of neurotoxin in 
the striatum. MPP+ was examined by HPLC 90 min after the second MIND4 administration. D-
G) Degeneration of dopaminerigic neurons was induced in mice using subacute MPTP-treatment 
paradigm (20mg/kg i.p. injection once daily for 4 days) and MIND4 administered by i.p. at 
established effective dose 60mg/kg) 10 min before and 50 min after each MPTP injection. D, E) 
MIND4 attenuated MPTP induced dopamine (DA) depletion  (D) and high DA turnover rate (E) 
(n=5-8). F) Stereological quantification of TH neurons (n=5-8). (* = p < 0.05; ** = p < 0.01; *** 
= p <  0.001). G) MIND4 treatment preserves SN dopaminergic neurons in MPTP mice. H-K) 
Analysis of pharmacodynamic markers in stiatal samples (D-G): NRF2 activation (increase 
GCLM levels) and SIRT2 inhibition (increase α-tubulin acetylation) in MPTP-challenged brains 
from MIND4-treated and untreated mice . Levels of GCLM (H) and acetylated α-tubulin (I) and 
α-tubulin (loading control) were detected by immunoblotting. J) Densitometry analysis of (H). 
Mean of GCLM signal is statistically significantly greater in MIND4-tretaed then in untreated 
samples (n=5). * = p < 0.5. K) Densitometry analysis of (I). Mean of acetylated α-tubulin shows 
no statistically significant difference in cohorts of MIND4-treated vs untreated cohorts. Levels of 
total α-tubuin were used for normalization in (J) and (K). 
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Fig. 2. Characterization of NRF2 inducer MIND4-17. A) Structure of parent MIND4 and lead-
inducer MIND4-17. B) Concentration-dependent activity test of MIND4-17, structural analogs 
MIND4-17-15, MIND4, MIND4B, and control NRF2 inducers SFP and DMF in quantitative 
NQO1 inducer bioassay. The standard deviation in each data point (n=8) < 5%. C-F, H) Levels of 
NRF2 and NRF2-responsive NQO1 and GCLM proteins and GADPH, β-actin, LAMIN used as 
loading control were detected by immunoblotting. C) Induction of NRF2-responsive NQO1 and 
GCLM proteins in MIND4 and DMF treated mutant HD ST14A cells. D) Compound activity test 
shows no induction of NQO1 in NRF2-KO MEFs treated with MIND4-17 and its analogs.  
Induced NQO1 level in wild-type MEFs is shown for comparison. E) Concentration-dependent 
stabilization of NRF2 protein in wild-type MEFs treated with MIND4-17, MIND4, MIND4B, or 
SFP. F) Time-dependent accumulation of NRF2 in cytoplasmic and nuclear fractions from wild-
type MEFs treated MIND4-17. Cell lysis and biochemical fractionation were performed at the 
indicated treatment times. G) MIND4-17 covalently modifies a single cysteine -151 in the BTB 
domain of KEAP1. Overlay of the deconvoluted intact protein mass spectra obtained from BTB 
[48-190/S182A] (theoretical mass 16175.6 Da) in buffer (red) vs. treated with MIND4-17 (blue). 
H) MIND4-17 treatment stabilizes NRF2 in COS1 cells co-expressing NRF2-V5 and KEAP1 
wild-type or double-mutant C226S/C613S KEAP1 but not a single mutant C151S.  
 
Fig. 3. MIND4-17 arrests KEAP:NRF2 complex in the closed conformation in live cells. A) 
Fluorescence lifetime imaging of cells co-expressing either EGFP-NRF2 + free mCherry or 
EGFP-NRF2 + KEAP1-mCherry, and treated with vehicle (DMSO) or MIND4-17 (1 µM) for 1 
h.  HEK293 cells were transfected with the indicated constructs, and the fluorescence lifetime of 
EGFP and the FRET efficiency quantified in the cytoplasm 24 h later. The first column shows the 
EGFP intensity images from which the lifetime data were derived, while the second column 
shows mCherry intensity images.  The third column depicts EGFP fluorescence lifetime where 
pixel color corresponds to the mean lifetime of EGFP, ranging from 1.9 to 2.5 ns as indicated in 
 35 
the color-scale below each image.  The fourth column shows the lifetime data histograms for each 
image, with lifetime on the x-axis and pixel frequency on the y-axis. B) Quantification of the 
open and closed conformations of the KEAP1:NRF2 protein complex based on the FRET 
efficiency distribution across the cytoplasm. The sub-population of FRET efficiency between 0-
15% was assigned the "open" conformation of the complex, while the FRET population between 
15-30% the "closed" conformation of the complex. Data represent means ± SD from 6 to 17 cells.    
 
Fig 4. NRF2 activation by MIND4-17 has anti-inflammatory effects in mouse microglia cells. A-
F) Evaluation of NRF2-specific transcriptional responses in resting and LPS-activated BV2 
microglial cells treated with MIND4-17. Concentration-dependent effects of MIND4-17 
treatment on mRNA expression of NRF2-responsive anti-oxidant GCLM (A) and NQO1 (B), and 
pro-inflammatory cytokine Il-6 (C), IL-1β (D), TNFa (E), and MCP-1 (F) genes. Transcriptional 
expression was measured using qRT-PCR with gene-specific primers in duplicates (n=2). Means 
(filled bars) and standard error bars are shown. G-H) MIND4-17 concentration-dependent effects 
on secretion of IL6 in primary microglia (G) and astrocytes (H) from wild-type (WT) and HD 
(YAC 128); inflammatory responses were induced with CSE and INF-γ. Combined graphs of two 
independent experiments are shown. Filled circles (WT) and open squares (YAC128) represent 
mean values (n=2) from compound-treated cells expressed as a percent from vehicle (DMSO)-
treated cells (100%), standard error bars are shown.  
NRF2 activation by MIND4-17 has anti-inflammatory effects in mouse microglia cells 
 
Fig. 5. Characterization of anti-inflammatory NRF2-dependent responses in primary human 
monocytes treated with MIND4-17. A-H) MIND4-17 represses expression of induced 
inflammatory cytokines in primary monocytes from normal subjects (A-D) and HD patients (E-
H).  IL-1b, IL-6, IL-8, and TNFα, production by LPS and IFN-γ stimulated monocytes, measured 
by multiplex ELISA, was compared in cells treated with different concentrations of MIND4-17 
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and with similar doses of vehicle (DMSO). Linear mixed model on log transformed data, n= 10 
controls, n= 13 for HD patients, +/- SEM,  * = p<0.05; ** = p<0.01, *** = p<0.001.  (One-Way 
ANOVA p=0.61, n= 13).  
 
Fig. 6. Activation of NRF2 signaling in human iPSC-derived neural stem cells. A) MIND4-17 
induces NQO1 and GCLM protein expression in HD48, HD51 and WT54, WT55 NSCs. Cells 
were treated with MIND4-17 for 24 h at indicated concentrations. Protein levels were detected by 
immunoblotting. B) No effects of MIND4-17 treatment on mutant or wild-type HTT levels in 
HD51 and WT55 NSCs in were detected. C) HD48 and HD51 extracts from (A) were diluted 1:3 
and NQO1 levels re-examined. D) Densitometric analysis of NQO1 expression in HD48 and 
HD51 (black bars) and WT54 (grey bars) NSCs. Data are presented as mean ± SD of two 
independent experiments. *p <0.05 by t-test; n=4. E) Relative induction of NQO1 expression in 
WT54 (grey triangle/line) and HD51 (black triangle/line) NSCs treated with MIND4-17 at 
indicated concentrations. Each data point represents a mean ± SD of two independent 
experiments; n=4. F-I) Effects of MIND4-17 in mutant HD4 and in genetically corrected isogenic 
non-disease HD116c. F) Basal levels of NQO1, GCLM, and a-tubulin in HD4 and HD116c, 
detected by immunoblotting. G, H) MIND4-17 induces expression of NQO1 and GCLM in the 
corrected HD116c (H) but not in the parental HD4 (G) cell lines. NQO1 and GCLM protein 
expression levels and α−tubulin were detected by immunoblotting. I-J) Densitometric analysis of 
NQO1 (I) and GCLM (J) induction in HD4 from (G) shows no induction of NRF2-responsive 
proteins by MIND4-17. Levels of α-tubulin served as the loading control and were used for 
normalization of NQO1 or GCLM signals. K) Densitometric analysis of NQO1 induction in 
HD116c. Signals were normalized to the levels of α-tubulin. Data are presented as means ± SD; 
t-test with Holm correction for multiple comparison.  ***p <0.01;  n=4. 
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Materials and Methods  
 
Formulation, tolerability, and pharmacokinetics of MIND4  
MIND4 was solubilized at 5mg/ml in 7.5% Cremophor EL (BASF)/2.375% Ethanol in PBS. 
Wild-type mice C57BL/6  (n=3) were subjected to compound treatment at escalated dosing from 
50 mg/kg up to a final dose of 275 mg/kg administered daily by intraperitoneal (i.p.) injection. No 
weight loss or sudden death were observed suggesting lack of acute toxicity of MIND4 in that 
dose range. Mice were sacrificed 2 h following the last drug administration and cortical samples 
isolated according to standard procedure and subjected to HPLC analysis as described (96, 97).  
Pharmacokinetics was performed in male C57BL/6 mice (n=3) at 0.5, 1.0, 2, 4, 8, and 24 h post 
i.p. injection of MIND4 at 50 mg/kg and collected serum samples analyzed by HPLC. Mice (n=3) 
were sacrificed at 0.5 h post i.p. injection of MIND4 at 50 mg/kg dose and isolated cortical 
samples were subjected to HPLC analysis.  
 
Quantification of MIND4 using HPLC-EC:  Frozen mouse cortical tissues were extracted in ice-
cold methanol containing 0.4% acetic acid (approximately 1:6 ratios), probe sonicated for 5 sec 
and centrifuged at 22.000 g for 20 min at 40 C. The supernatant was dried under centrifugation 
and vacuum and reconstituted with running buffer.  Reverse phase- HPLC/ECA separation was 
accomplished on Shiseido MG240 C18 HPLC column (4.6x250 mm, 3 µ particle size), flow rate 
1ml/min, using 50% methanol in 0.1M sodium phosphate buffer pH 3, isocratic elution was 
performed for 20 min using 4 channel electrochemical array. Levels of MIND4 were determined 
using integrated peak areas and the standard probe.  
 
Analysis of TNFa levels in cortex of MIND4-terated R6/2 mice  
Female R6/2 mice used in the study were generated by back-crossing R6/2 males from 
The Jackson Laboratory, Bar Harbor, ME with C57BL/6 X CBA F1 females and maintained at 
MGH animal facility. Mice were genotyped by PCR using tail-tip DNA and were housed five per 
cage under standard conditions with ad libitum access to water and food. Mice were administered 
with MIND4 at the dose of 50 mg/kg by i.p. injections for 2 weeks. The drug suspension at 
5mg/ml in 7.5% Cremophor EL (BASF)/2.375% Ethanol in PBS, was made fresh daily. At 10 
weeks of age, R62 and age-matching wild type control mice were sacrificed 2 h after last 
injections, brains were removed and snap frozen in liquid nitrogen and kept frozen at -800 C until 
analyzed. All animal experiments were carried out in accordance with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals and were approved by local animal 
care committee. 
 
SIRT2 deacetylase activity test 
Deacetylation reaction was performed at 370C for 1hr in the presence of human recombinant 
enzymes: SIRT2 (BioMol-SE-251) 5 units/per reaction, compound of interest, standard buffer, 
50µM substrate, and 500µM NAD+ according to manufacturer protocol and as described 
previously (55). 
 
Compound activity test in the rat embryonic striatal cell lines ST14A 
ST14A cells (a generous gift of E. Cattaneo) (92) stably express either a mutant expanded repeat 
(128Q) or wild-type (26Q) 546 amino acid huntingtin (HTT) fragment and were treated with 
compounds for 24 h as described (93). Protein levels of NQO1, GCLM, and α-tubulin (loading 
control) were detected in ST14A by immunoblotting with NQO1 (Sigma, 1:1,000), GCLM 
(Abcam, 1:800), and GAPDH (Millipore, 1:10,000) antibodies.  
 
Nuclear-cytoplasmic extract separation 
Nuclear WT MEFs (500,000 per dish) were grown for 24 h on 6 cm plates, and then treated with 
solvent control (0.1% DMSO, v/v) or 0.5 µM MIND4-17. At the end of each treatment time, cells 
were washed twice in PBS and lysed in buffer A [10 mM KCl, 5 mM MgCl2, 50 mM Tris-HCl 
(pH 7.5), 0.5% NP-40, 1 mM DTT], containing 1 protease inhibitor and 1 phosphatase inhibitor 
tablets (Roche) per 10 mL buffer. Lysates were subjected to centrifugation at 1,000 x g for 5 min 
at 4°C and supernatant (cytoplasmic fraction) was transferred to a fresh microfuge tube. The 
pellet (nuclear fraction) was washed three times in buffer A before being dissolved in buffer B 
[2% SDS, 150 mM NaCl, 65 mM Tris-HCl (pH 8.0)] and sonicated for 30 sec. Finally, the lysates 
were subjected to Western blot analysis with NRF2 antibody and with GAPDH (rabbit 
polyclonal, 1:5000) and lamin A/C (rabbit polyclonal, 1:1000, Gene Tex) to confirm fraction 
purity and equal protein loading. 
 
Design and synthesis of MIND4-17 analogs 
MIND4-17 analogs 2286, 2291 and 2907 were synthesized as shown in Scheme 1 (Fig. S3). 
Compound A was prepared following a previously reported method (61). Compound A was 
converted to 2291, 2907 and MIND4-17 by reacting with 4-nitroflurobenzene, 2-chloro-5-
nitropyridine and 2-chloropyridine respectively. The nitro group in MIND4-17 was then reduced 
with stannous chloride to give 2286. 2909 was synthesized as shown in Scheme 2 (Fig. S3). 
Compound B was synthesized by coupling 2-chloro-5-nitropyridine and tert-butyl methyl 
malonate (60). Treatment of Compound B with hydrazine gave compound C, which upon 
reaction with 3-phenoxy acetyl chloride gave compound D. 2909 was obtained by reacting 
compound D with aniline and phosphorous trichloride. 2872 was prepared as shown in Scheme 3 
(Fig. S3). Compound E was obtained by reacting phenol with ethyl bromoacetate under basic 
conditions. The ester group in compound E was converted the hydrazide F by reacting with 
hydrazine. Compound F was reacted with phenylisocyanate and cyclized under basic condition to 
yield compound H, which was reacted with 2-chloro-5-nitropyridine to give 2872. Synthesis of 
MIND4-17 and respective analogs was conducted by a drug discovery company Aurigene (co-
authors V.P. and S. S); NMR analysis shows an acceptable 95% purity. The activities of MIND4-
17, synthesized by Aurigene, and commercially purchased from Cambridge (multiple batches) 
were identical and activities of analogs consistent with established mechanism. 
 
Compound GSH sensitivity assay.  
Hepa1c1c7 cells. Each compound was incubated in cell culture medium in the presence or 
absence of 1mM GSH at 37ºC for 30 min before administering to Hepa1c1c7 cells grown on 96-
well plates. After a 48 h exposure, the NQO1 enzyme activity was determined in cell lysates. 
Results are shown as average values of 8 replicate wells. The standard deviation in each case was 
less than 5%. 
 
Fluorescence lifetime imaging analysis of MIND4-17effect on NRF2 : KEAP1 complex  
 Fluorescence lifetime imaging microscopy (FLIM) was performed as described (Llères et al , 
2009) using an inverted multiphoton laser-scanning microscope (Zeiss LSM780 Confocal) with a 
63x oil immersion NA 1.4 Plan-Apochromat objective from Zeiss. The software used to run the 
LSM780 multiphoton microscope was Zen 2010. The microscope was equipped with a black 
incubation chamber suitable to maintain the live cells and optics at constant temperature 37 °C. 
Two-photon excitation of EGFP was achieved using a Coherent Scientific Chameleon Ultra II 
Ti:Sapphire laser (tuning range 680-1080 nm) at 890 nm. The fluorescence lifetime imaging 
capability was provided by time-correlated single photon-counting (TCSPC) electronics (SPC-
830; Becker & Hickl GmbH). Laser power was adjusted to give a mean photon count rate of the 
order 104–105 photons/s. Fluorescence lifetime measurements were acquired over 90 s. 
Fluorescence lifetimes were calculated for all pixels in the field of view (256 × 256 pixels) and 
then a particular region of interest (e.g., cytoplasm) was selected using SPCImage software 
(Becker & Hickl GmbH). The analysis of the FLIM measurements from a particular region of 
interest was performed by using SPCImage software. The best-fitting model (k2 of the fit close to 
one) to extract an accurate fluorescence lifetime value from the decays was applied by adjusting 
several parameters such as the number of exponential components, the background threshold, the 
shift index and the scatter parameter (amount of scattered excitation light detected). 
The FRET efficiency percentage was calculated using SPCImage software for the same region 
defined to calculate the mean fluorescence lifetime. The image was then analyzed using a two-
component exponential decay model were the lifetime t2 (non-interacting proteins lifetime from 
EGFP-NRF2 +free mCherry cells) was fixed, whereas the t1 value (lifetime associated to the 
donor proteins interacting with the acceptor) was left unchecked. Pixel enrichment in the 
respective FRET populations related to open (0-15%) or closed (15-30%) conformation was 
quantified from the lifetime distribution histograms. The lifetime histogram for each vehicle and 
MIND4-17 treated cells was normalized by the total number of pixels Fi = fi/Ni, where fi and Ni 
are the lifetime histogram and the total number of pixels, respectively. 
 
Mass spectrometry analysis of KEAP1 BTB modification by MIND4-17 
The BTB domain of Keap1 (residue 48-190) was cloned into a modified pET19 vector with N-
terminal 6xHis-tag cleavable with TEV protease and a single point mutation was introduced at 
position 182 (S182A). The full length KEAP1 with deletion of the first 54 amino acids was 
cloned in similarly in the same expression vector.  The overexpression and purification were 
performed as described in (66).   
For analysis of the potential modification of the BTB domain, 10 µM BTB [48-190 S182A] were 
incubated with 2mM MIND4-17 (or DMSO 2% final concentration for control) for an hour on ice 
in 20 mM TrisHCl pH 8.0, 150 mM NaCl. Intact protein masses were determined through HPLC-
coupled ESI-MS on an AB Sciex TripleTOF 5600+ mass spectrometer (Sciex, Darmstadt, 
Germany). Intact protein were first concentrated and washed on a Piccolo Proto 200 C4 5µm 2.5 
x 0.5mm trap column (Higgins Analytical, Mountain View, CA) and subsequently switched in 
line with, and separated on, a Jupiter C4 5µm 300Å 150 x 1 mm analytical column (Phenomenex, 
Torrance, CA) mounted onto a Shimadzu Prominence UFLC (Shimadzu, Duisburg, Germany) at 
a 70µl min-1 flow rate with the following buffers: A – 5% ACN, 5% DMSO, and 0.1% FA; B – 
90% ACN, 5% DMSO, and 0.1% FA. Proteins were then eluted over with a gradient of 3 minutes 
of 1% B to 55% B followed by 1 minute of 55% B to 90% B. Mass analysis was performed by 
ESI-TOF-MS on an AB Sciex TripleTOF 5600+ mass spectrometer (Sciex, Darmstadt, Germany) 
with a DuoSpray Ion Source with the following settings: floating voltage of 5500V, temperature 
of 350°C, declustering potential of 120 with 4 separate TOF experiments each respectively with 
4, 12, 20 and 40 time bins summed. Data analysis was performed as follows: spectra were 
integrated over a retention time period, and the summed TOF experiment with the greatest 
resolution selected. The raw data was then converted and deconvoluted using the MaxEnt I 
algorithm (Waters, Milford, MA) at a resolution of 0.1 Da. 
 
Proteomic analysis by quantitative Mass-Spectrometry  
Preparation of mass-spectrometry samples for reactive cysteine profiling: HeLa soluble protein 
lysates (500 uL, 2 mg mL-1) were aliquoted, and MIND4-17 (10 µM), or DMSO was added to 
the appropriate samples at the designated concentration. Two aliquots were made for each 
inhibitor concentration or DMSO equaling 4 tubes for one final sample. The samples were 
incubated at RT for 1 h. IA-alkyne (100 µM) was added to the samples and incubated at RT for 1 
hr. Inhibitor treated and DMSO samples were functionalized with Azo-H tag or Azo-L tag (100 
µM, 50X stock in DMSO) respectively (68). All samples were then treated with TCEP (1 mM, 
50X fresh stock in water), TBTA ligand (100 µM, 17X stock in DMSO:t-butanol = 1:4), and 
copper(II) sulfate (1 mM, 50X stock in water) followed by incubation at RT for 1 hr. Samples 
were combined pairwise to combine inhibitor and DMSO-treated samples and centrifuged (6500 
g, 4 min, 4 °C) to pellet the precipitated proteins. The pellets were resuspended in cold methanol 
by sonication and the two samples were combined. Centrifugation was followed by a second 
methanol wash, after which the pellet was solubilized in DPBS containing 1.2% SDS via 
sonication and heating (90 °C, 5 min). The 2 samples resulting from inhibitor pretreatment, IA-
alkyne incubation, and Azo-H or Azo-L labeling are as follows: Heavy (DMSO, 100 µM IA-
Alkyne)/light (10 µM MIND4-17, 100 µM IA-Alkyne). 
The SDS-solubilized proteome samples were diluted by 5 mL of DPBS for a final SDS 
concentration of 0.2%. The solution was incubated with 100 µL of streptavidin-agarose beads 
(Thermo Scientific, washed 3X with DPBS to remove storage buffer) overnight at 4 °C. Samples 
were rotated at RT for 2 h before washed by 5 mL 0.2 % SDS/DPBS, 3 X 5 mL DPBS, and 3 X 5 
mL water. The beads were pelleted by centrifugation (1400 X g, 3 min) between washes. 
The washed beads were suspended in 500 uL of 6 M urea/DPBS and 10 mM DTT (from 20X 
stock in water) and places in a 65 °C heat block for 15 min. Iodoacetamide (20 mM from 50X 
stock in water) was then added and the samples were allowed to react at 37 °C for 30 min. 
Following reduction and alkylation, the beads were pelleted by centrifugation and resuspended in 
200 µL of 2 M urea/DPBS, 1 mM CaCl2 (100X stock in water), and trypsin (2 µg). The digestion 
was allowed to proceed over night at 37 °C. The beads were pelleted by centrifugation and 
washed with 3 X 500 µL DPBS and 3 X 500 µL water. The azobenzene cleavage was carried out 
by incubating the beads with 50 µL of 25 mM sodium dithionite at RT for 1 h. The cleavage 
process was then repeated twice with 75 µL of 25 mM and 50 mM sodium dithionite and all the 
supernatants were combined. The beads were then washed twice with 75 µL of water and the 
wash was combined with the supernatant from the cleavage step to reach 350 µL final. Formic 
acid (17.5 µL) was added to the sample, which was stored at -20 °C until mass spectrometry 
analysis. 
Quantitative mass-spectrometry analysis: LC/LC-MS/MS analysis was performed on an LTQ-
Orbitrap Discovery mass spectrometer (ThermoFisher) coupled to an Agilent 1200 series HPLC. 
Peptide digests were pressure loaded onto a 250 µm fused silica desalting column packed with 4 
cm of Aqua C18 reverse phase resin (Phenomenex). The peptides were eluted onto a biphasic 
column (100 µm fused silica with a 5 µ, tip, packed with 10 cm C 18 and 4 cm Partisphere strong 
cation exchange resin (SCX, Whatman)) using a gradient 5-100% Buffer B in Buffer A (Buffer 
A: 95% water, 5% acetonitrile, 0.1% formic acid; Buffer B: 20% water, 80% acetonitrile, 0.1% 
formic acid). The peptides were then eluted from the SCX onto the C18 resin and into the mass 
spectrometer using 4 salt steps previously described (71). The flow rate through the column was 
set to ~0.25 µL/min and the spray voltage was set to 2.75 kV. One full MS scan (FTMS) (400-
1800 MW) was followed by 8 data dependent scans (ITMS) of the nth most intense ions. 
The tandem MS data were searched using the SEQUEST algorithm (69) using a concatenated 
target/decoy variant of the human IPI databases. A static modification of +57.02146 on cysteine 
was specified to account for alkylation by iodoacetamide and differential modifications of 
+462.2987 (IA-alkyne and cleaved Azo-H) and +456.2849 (IA-alkyne and cleaved Azo-L) were 
specified on cysteine to account for probe modifications. SEQUEST output files were filtered 
using DTASelect (70). Quantification of heavy/light ratios (RH/L) was performed using the 
CIMAGE quantification package as previously described (67). 
Quantitative mass-spectrometry data for reactive-cysteine profiling upon MIND4-17 treatment: 
Cysteine reactivity in proteomes pre-treated with MIND4-17 (Heavy-labeled) were compared to 
DMSO-treated samples (Light-labeled). For every cysteine-containing peptide, a heavy:light ratio 
was calculated that reflects the extent of cysteine reactivity in the inhibitor-treated versus DMSO 
samples. A ratio of 1 indicates that there was no change in cysteine reactivity, whereas ratio 
values >>1 show a loss in cysteine reactivity upon inhibitor treatment. Cysteine-containing 
peptides with ratio >2 for MIND4-17 are highlighted in green in Dataset SI, submitted as Excel 
spreadsheet.  
 
Macrophages for drug testing experiment 
Immortalized mouse bone marrow derived macrophages were a kind gift of Dr. Katherine 
Fitzgerald (UMASS Medical Center). Primary cells were immortalized by infection with J2 
retrovirus as described (77). The LPS activation of macrophages, drug treatment, and 
transcriptional profiling (Fig. S3) were conducted similar to experimental conditions described 
for microglia BV2 cells. 
Compound transcriptional expression profiling microglia BV2 cells and macrophages 
The following qPCR primers were selected using PrimerBank 
(http://pga.mgh.harvard.edu/primerbank/) database: 
mIL-1beta for 5'-GCAACTGTTCCTGAACTCAACT-3' 
mIL-1beta rev 5'-ATCTTTTGGGGTCCGTCAACT-3' 
mIL-6 for 5'-TAGTCCTTCCTACCCCAATTTCC-3' 
mIL-6 rev 5'-TTGGTCCTTAGCCACTCCTTC-3' 
mGAPDH for 5'-TGTGTCCGTCGTGGATCTGA-3' 
mGAPDH rev 5'-GGTCCTCAGTGTAGCCCAAG-3' 
mNQO1 for 5'-AGGATGGGAGGTACTCGAATC-3' 
mNQO1 rev 5'-AGGCGTCCTTCCTTATATGCTA-3' 
mGCLM for 5'-AGGAGCTTCGGGACTGTATCC-3' 
mGCLM rev 5'-GGGACATGGTGCATTCCAAAA-3' 
mTNFalpha for 5'-CCCTCACACTCAGATCATCTTCT-3' 
mTNFalpha rev 3'-GCTACGACGTGGGCTACAG-3' 
mMCP-1 for 5'-TTAAAAACCTGGATCGGAACCAA-3' 
mMCP-1 rev 5'-GCATTAGCTTCAGATTTACGGGT-3' 
 
Isolation and culturing primary astrocytes and microglia cells 
Whole brains were obtained from postnatal 1 to 3 d old wild-type and YAC128 mouse pups on 
the FVB/N strain background and placed in Hank's Balanced Salt Solution (Invitrogen) on ice. 
Meninges were removed and the remaining brain tissue was placed into growth medium (DMEM, 
10% FBS, 1% L-glutamine, 1% penicillin/streptomycin), and homogenized. Cells from each 
brain were pelleted, re-suspended in growth medium, transferred into a T150 flask, and cultured 
at 37ºC. Growth medium was replaced after 24 h and thereafter every 7 d. After 18 to 21 d in 
culture, loosely attached microglia were harvested and seeded at 1.4 x 105 cells/ml with pre-
incubated conditioned media into 96-well tissue culture plates. Adherent astrocytes were plated at 
1.4 x 105 cells/ml in 10% FBS media for 24 h in 96-well tissue culture plates. 
 
MIND4-17 activity test on cytokine expression in primary human HD and non-disease monocytes 
Cells were isolated from whole blood, as previously described (40). In brief, monocytes were 
sorted via magnetic cell separation columns using anti-CD14 microbeads (Miltenyi Biotec). 
Monocytes were seeded at 1 x 105 cells per well in 96-well tissue culture plates with R10 media 
(RPMI culture medium supplemented with 10% FCS, 2 mM L-glutamine, 50 U/ml penicillin and 
50 mg/ml streptomycin). After resting for 16 h, the culture media was replaced with R10 media 
containing either vehicle (DMSO) or MIND4-17 at different concentrations (0.3, 1, and 3 µM). 
After 24 h of compound treatment, media was changed again using R10 containing both MIND4-
17 at the same concentration and, to stimulate cytokine production, 10 ng/ml INF-γ (R&D 
Systems) and 2 mg/ml lipopolysaccharide (LPS, Sigma-Aldrich). Supernatants were collected at 
24 h, and stored at -70°C. Supernatants were analyzed using the human pro-inflammatory II (4-
plex) MSD assay measuring IL-1β, IL-6, IL-8 and TNFα. Cytokine levels were normalized to 
total protein concentration in each well. Cells were lysed in 50 mM Tris pH 8, 150 mM NaCl, 
0.5% SDS, and 0.5% Triton X-100 and assayed for total protein concentration using a BCA assay 
(Thermo-Fisher). Cytokine production in vehicle treated controls peaked at a DMSO 
concentration that was needed to achieve 1µM compound treatment dose, in an apparent MIND4-
17 independent DMSO-mediated effect. Despite this unexplained stimulation by this DMSO 
concentration, inhibitory effects of MIND4-17 on cytokine production in primary human control 
and HD monocytes were readily detectable. 
To test for toxic effects of MIND4-17 on primary human leukocyte cultures, monocytes were 
treated with MIND4-17 but not IFN-γ and LPS, mimicking the treatment duration used in the 
cytokine profiling experiments (Fig. S5). Cell death was measured using a LDH assay (CytoTox-
Fluor Cytotoxicity Assay, Promega). 
 
Human iPS cell lines and differentiation of neuronal stem cells  
iPSCs were maintained on MEF feeders prepared using mitomycin C. Normal growth medium 
was: Knockout DMEM/F12 (Life Technologies #12660-012) with 20% knockout serum 
replacement (Life Technologies #10828-028), 1 mM L-glutamine (Life Technologies #35050-
061), 1x MEM non-essential amino acids (Life Technologies #11140-050), 100 µM 2-
mercaptoethanol and 50 units/mL penicillin/streptomycin (Life Technologies #15070-063). 
Genomic DNA was prepared using DNeasy Mini Kit (Invitrogen) from ≈106 cells pelleted after 
accutase passage. 25 µL reaction mix included 0.25 µg genomic DNA, 1xGoTaq Buffer 
(Promega), 1x GoTaq DNA Polymerase (Promega), 200 µM DNTPs, 200 nM forward/reverse 
primers, 5% DMSO. PCR products were run on a 4% NuSieve 3:1 Agarose gel (Lonza) at 95V 
for 3 hrs. Primers and PCR amplification protocol of CAG triplet repeats have been used as 
previously described (98). Genotype was confirmed by PCR amplification of genomic DNA (Fig. 
S6A). 
NSCs were established based on a protocol described for mouse ES cells (82).  iPSCs were 
passaged with 1 mg/mL collagenase type I (Life Technologies #17018-029) in DMEM (Life 
Technologies #11995-073) on to 0.1% gelatin coated plates (Sigma #G1393) with NSC media: 
Advanced DMEM/F12 (Life Technologies #12634-028) with 2 mM L-glutamine, 50 units/ml 
penicillin/streptomycin, retinoic acid-free B27 supplement (Life Technologies #12587-010), N2 
supplement; supplemented with 100 ng/mL FGF (Invitrogen #PHG0023), 100 ng/mL EGF 
(Invitrogen #PMG8041), 5 µg/mL heparin(Sigma #H3149), and 1% knockout serum replacement. 
Over 5-14 days, bipolar cells were observed to stream out of attached colonies. When cells had 
formed a 60-80% confluent monolayer of bipolar cells, cells were passaged with Accutase 
(Sigma, #A6964) for 2-5 min until detached, then centrifuged 3 min, and remaining clumps of 
cells disrupted with a p1000 pipet tip. Cells were then re-plated as a single cell suspension 1:1 
onto 0.1% gelatin coated plastic, in NSC media, without additional knockout serum and with 20 
ng/mL FGF, 20 ng/ml EGF, and 5 µg/ml heparin. Cells were maintained in NSC media, without 
knockout serum and with 20 ng/ml FGF, 20 ng/ml EGF, and 5 µg/ml heparin on 0.1% gelatin 
coated plastic and passaged with Accutase as previously described 1:2-1:4 for the first four 
following passages, then 1:2-1:10 during later passages. NSCs were routinely tested for 
expression of the radial glial marker nestin by immunofluorescence, and by immunoblotting for 
presence of neuronal marker β-III-tubulin, absence of astrocytic marker glial fibrillary acid 
protein (GFAP), and for expression of normal and mutant huntingtin using anti-huntingtin 
antibody Ab1 (against aa 1-17) by Western blot (Fig. S6B, C).  
 
Figure Legends 
 
Fig. S1. MIND4 pharmacokinetics in serum (filled circles) were examined by HPLC analysis in 
wild-type male C57BL/6 mice (n=3) at 0.5, 1.0, 2, 4, 8, and 24 h at compound treatment dose 50 
mg/kg; blood Cmax=477 ng/ml at 0.5 h time point. Brain levels (red triangle) were analyzed in 
cortices from mice (n=3) sacrificed at 0.5 h post i.p. injection; Cbrain=120 ng/ml and respective 
brain/serum ratio 0.25. 
 
Fig. S2. Characterization of MIND4-17 and its structural analogs. A) Structures of MIND4-17 
and lead-series of structural analogs. Established NQO1 CD and SIRT2 IC50 are shown. B, C) 
Dose-response activity tests of MIND4-17 and MIND4-17 analogs in wild type mouse embryonic 
fibroblasts (MEF): (B) wild type and (C) KEAP1-null. Cells were treated with compounds for 24 
h. Levels of induced NQO1 protein and β-actin (loading control) were detected by 
immunoblotting. D-F) Testing NRF2 inducing properties of MIND4-17 analogs in structure-
activity relationship (SAR) study of MIND4-17 in ST14A cells. D) Structures of MIND4-
17analogs: 2872, 2286, 2291, 2907, 2909, used in SAR study. E, F) Dose-response activity tests 
of MIND4-17 analogs in rat embryonic ST14A cells. Levels of NQO1, GCLM and loading 
control α-tubulin were detected by immunoblotting. Cells were treated with compounds for 24 h. 
G, H) Negative effects of GSH on the NQO1 inducer activity of (G) MIND4-17 and MIND4 and 
(H) MIND4-17-33 and MIND4-17-56 (G) analogs in Hepa1c1c7 cells. Each compound was 
incubated in cell culture medium in the presence or absence of 1mM GSH at 37ºC for 30 min 
before administering to cells. After a 48 h exposure, the NQO1 enzyme activity was determined 
in cell lysates. Results are shown as average values of 8 replicate wells. The standard deviation in 
each case was less than 5%.  
 
Fig. S3. Design and synthesis schemes of MIND4-17 analogs 2872, 2286, 2291, 2907, and 2909 
for SAR study. Scheme 1: a) K2CO3, DMF, 100oC, 1h; b) SnCl2.2H2O, EtOH, reflux; c) 
Pd2(dba)3, Xanthphos, Hunig's base, Dioxane reflux. Scheme 2: a) EtOH, reflux; b) DCM, Et3N, 
rt; c) PCl3, 1,2-dichlorobenzene, 190oC. Scheme 3: a) Acetone, K2CO3 reflux; b) EtOH, reflux; c) 
2N KOH reflux; d) K2CO3, DMF, 100oC. 
 
Fig. S4. Treatment with MIND4-17 reduces expression of pro-inflammatory cytokines. A-F) 
Evaluation of NRF2-specific transcriptional responses in rested and LPS-activated iBMM 
macrophages treated with MIND4-17. Concentration-dependent effects of MIND4-17 on mRNA 
expression of NRF2-responsive genes GCLM (A) and NQO1 (B), and inflammatory factors Il-6 
(C), IL-1β (D), TNFα (E), and MCP-1 (F), and effects of MIND4 at 3 µM on TNFα (G), 
Transcriptional expression was measured using qRT-PCR with gene-specific primers and 
assessed in duplicates (n=2). Means (filled bars) and standard error bars are shown. H-K) MIND4 
treatment represses expression of inflammatory TNFα protein in brain of HD mouse model R6/2. 
H, I) TNFα and GAPDH protein levels were detected by immunoblotting in cortical extracts 
from 10-week old wild type (n=7) and R6/2 (n=7) mice (H) and in R6/2 mice treated by for 2 
weeks with vehicle (control) (n=5) or MIND4 (n=9) at 50 mg/kg, administered by daily i.p. 
injections (I). GAPDH levels were used as loading control. J) Quantification analysis of TNFα 
levels (H) in wild type (open bars) and in R6/2 (black bars) brain samples shows no statistical 
difference. GAPDH protein was used to normalize TNFα levels. K) Quantification analysis of 
TNFα levels (KI in vehicle-treated (black bars) and in MIND4-treated (grey bars) R6/2 brain 
samples. GAPDH protein was used to normalize TNFα levels. MIND4 treatment resulted in 
statistically significant reduction of TNFα levels in HD cortices.   Student’s t-test, *** P<0.001. 
 
Fig. S5. MIND4-17 mediates anti-inflammatory NRF2 activation responses in human primary 
monocytes from HD patients and healthy controls. A-B) MIND4-17 represses expression of 
induced inflammatory cytokines in primary monocytes from HD patients and non-disease 
controls. Expression levels are shown IL-1 (D), IL-6 (E), IL-8 (F), and TNFα (G) production by 
IFN-γ− and LPS-stimulated HD patient monocytes. Cytokine expression, measured by 
multiplexed ELISAs, was compared in cells treated with 3 µM MIND4-17 or vehicle (DMSO). 
(Linear mixed model on log transformed data, n=10 non-disease, n=13 for HD patients, *p< 0.05; 
**p< 0.01, ***p< 0.001.) E) MIND4-17 is not toxic for human monocytes. Lack of apparent 
toxicity of MIND4-17 treatment at tested doses. 48 h treatment of primary human monocytes 
with MIND4-17 and vehicle does not show any effect on cell viability measured with LDH-
assays.  
 
Fig. S6. Characterization of human neuronal HD and non-disease cells, neural stem cells and 
mature neurons. A) PCR analysis of CAG triplet repeat length on genomic DNA from human 
NSC WT54 (17CAG); HDc116 (containing corrected to wild type 21CAG); HD48 (mutant allele 
with 42 CAGs); HD51 (mutant allele with 50 CAGs); HD4-parent of HDc116 (containing 
72CAGs). The expected sizes of mutant 42 CAG, 50 CAG and 72CAG PCR products in 
respective ranges of 180-210 bp, 250-300 bp, and 350-450bp respectively are shown with 
reference to DNA ladder standard. B) Western blot analysis of expression wild type and mutant 
HTT (indicated by arrows) of NSC cell lines detected using anti-HTT antibody Ab1 against 1-
17aa of HTT. C) Immunofluorescence microscopy using anti-Nestin antibody of human NSCs 
derived from iPSCs. Percentages of cells positive for Nestin staining: WT54, 98.75% (n=80 
cells); HDc116, 99% (n=301 cells); HD48, 98.92% (n=556 cells); HD51, 98.25% (n=228 cells); 
HD4, 100% (159 cells). 
 
SI Dataset. (Submitted as Excel spreadsheet table). Quantitative mass-spectrometry data for 
reactive cysteines modified by MIND4-17 treatment. Cysteine reactivity in proteomes pre-treated 
with MIND4-17 (Heavy-labeled) were compared to DMSO-treated samples (Light-labeled). For 
every cysteine-containing peptide, a heavy:light ratio was calculated that reflects the extent of 
cysteine reactivity in the inhibitor-treated versus DMSO samples. A ratio of 1 indicates that there 
was no change in cysteine reactivity, whereas ratio values >>1 show a loss in cysteine reactivity 
upon inhibitor treatment. Four cysteine-containing peptides with ratio >2, modified by MIND4-
17, are shown at top of the table and highlighted in green.  
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